Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects

British Journal of Clinical Pharmacology

Volumn 71, Issue 6, 2011, Pages 886-898

  Liem Moolenaar, Marieke ^a   de Boer, Peter ^b   Timmers, Maarten ^b   Schoemaker, Rik C ^a   van Hasselt, J G Coen ^a   Schmidt, Stephan ^c   van Gerven, Joop M A ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Healthy subjects; Non linear mixed effect modelling; Pharmacokinetic pharmacodynamic relationships; Pharmacology; Scopolamine

Indexed keywords

PLACEBO; SCOPOLAMINE;

ADULT; ALERTNESS; ANTICHOLINERGIC EFFECT; ARTICLE; BLURRED VISION; BODY EQUILIBRIUM; CENTRAL NERVOUS SYSTEM FUNCTION; CONTROLLED STUDY; DIZZINESS; DROWSINESS; DRUG EFFECT; DRUG HALF LIFE; DRUG RETENTION; DRUG SAFETY; HEART PALPITATION; HEART RATE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NONLINEAR SYSTEM; NORMAL HUMAN; PRIORITY JOURNAL; SACCADIC EYE MOVEMENT; SIDE EFFECT; VISUAL ANALOG SCALE; XEROSTOMIA;

ADOLESCENT; ADULT; CENTRAL NERVOUS SYSTEM; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MUSCARINIC ANTAGONISTS; SACCADES; SCOPOLAMINE HYDROBROMIDE; YOUNG ADULT;

EID: 79955868932     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.03936.x     Document Type: Article

References (60)

1. Deutsch JA. The cholinergic synapse and the site of memory. Science 1971; 174: 788-94.
2. Renner UD, Oertel R, Kirch W. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. Ther Drug Monit 2005; 27: 655-65.
3. Peroutka SJ, Snyder SH. Antiemetics: neurotransmitter receptor binding predicts therapeutic actions. Lancet 1982; 1: 658-9.
4. Ebert U, Kirch W. Scopolamine model of dementia: electroencephalogram findings and cognitive performance. Eur J Clin Invest 1998; 28: 944-9.
5. Ebert U, Siepmann M, Oertel R, Wesnes KA, Kirch W. Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. J Clin Pharmacol 1998; 38: 720-6.
6. Ebert U, Grossmann M, Oertel R, Gramatte T, Kirch W. Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers. J Clin Pharmacol 2001; 41: 51-60.
7. Vitiello B, Martin A, Hill J, Mack C, Molchan S, Martinez R, Murphy DL, Sunderland T. Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans. Neuropsychopharmacology 1997; 16: 15-24.
8. Hall ST, Puech A, Schaffler K, Wesnes K, Gamzu ER. Early clinical testing of cognition enhancers: prediction of efficacy. Pharmacopsychiatry 1990; 23 (Suppl. 2): 57-8.
9. Riedel WJ, Jolles J. Cognition enhancers in age-related cognitive decline. Drugs Aging 1996; 8: 245-74.
10. Broks P, Preston GC, Traub M, Poppleton P, Ward C, Stahl SM. Modelling dementia: effects of scopolamine on memory and attention. Neuropsychologia 1988; 26: 685-700.
11. Bartus RT. Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine. Pharmacol Biochem Behav 1978; 9: 833-6.
12. Araujo JA, Studzinski CM, Milgram NW. Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 411-22.
13. Araujo JA, Chan AD, Winka LL, Seymour PA, Milgram NW. Dose-specific effects of scopolamine on canine cognition: impairment of visuospatial memory, but not visuospatial discrimination. Psychopharmacology (Berl) 2004; 175: 92-8.
14. Ghoneim MM, Mewaldt SP. Studies on human memory: the interactions of diazepam, scopolamine, and physostigmine. Psychopharmacology (Berl) 1977; 52: 1-6.
15. Green A, Ellis KA, Ellis J, Bartholomeusz CF, Ilic S, Croft RJ, Phan KL, Nathan PJ. Muscarinic and nicotinic receptor modulation of object and spatial n-back working memory in humans. Pharmacol Biochem Behav 2005; 81: 575-84.
16. Siegfried KR. Pharmacodynamic and early clinical studies with velnacrine. Acta Neurol Scand Suppl 1993; 149: 26-8.
17. Prohovnik I, Arnold SE, Smith G, Lucas LR. Physostigmine reversal of scopolamine-induced hypofrontality. J Cereb Blood Flow Metab 1997; 17: 220-8.
18. Preda L, Alberoni M, Bressi S, Cattaneo C, Parini J, Canal N, Franceschi M. Effects of acute doses of oxiracetam in the scopolamine model of human amnesia. Psychopharmacology (Berl) 1993; 110: 421-6.
19. Jones RW, Wesnes KA, Kirby J. Effects of NMDA modulation in scopolamine dementia. Ann N Y Acad Sci 1991; 640: 241-4.
20. Caine ED, Weingartner H, Ludlow CL, Cudahy EA, Wehry S. Qualitative analysis of scopolamine-induced amnesia. Psychopharmacology (Berl) 1981; 74: 74-80.
21. Curran HV, Schifano F, Lader M. Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood. Psychopharmacology (Berl) 1991; 103: 83-90.
22. Bartus RT, Dean RL III, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-14.
23. Drachman DA, Leavitt J. Human memory and the cholinergic system. A relationship to aging? Arch Neurol 1974; 30: 113-21.
24. Kopelman MD, Corn TH. Cholinergic 'blockade' as a model for cholinergic depletion. A comparison of the memory deficits with those of Alzheimer-type dementia and the alcoholic Korsakoff syndrome. Brain 1988; 111 (Pt 5): 1079-110.
25. Sunderland T, Weingartner H, Cohen RM, Tariot PN, Newhouse PA, Thompson KE, Lawlor BA, Mueller EA. Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls. Psychopharmacology (Berl) 1989; 99: 129-33.
26. Drachman DA. Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology 1977; 27: 783-90.
27. Martinez R, Molchan SE, Lawlor BA, Thompson K, Martinson H, Latham G, Weingartner H, Sunderland T. Minimal effects of dextroamphetamine on scopolamine-induced cognitive impairments in humans. Biol Psychiatry 1997; 41: 50-7.
28. Beatty WW, Butters N, Janowsky DS. Patterns of memory failure after scopolamine treatment: implications for cholinergic hypotheses of dementia. Behav Neural Biol 1986; 45: 196-211.
29. Christensen H, Maltby N, Jorm AF, Creasey H, Broe GA. Cholinergic 'blockade' as a model of the cognitive deficits in Alzheimer's disease. Brain 1992; 115: 1681-99.
30. Molchan SE, Martinez RA, Hill JL, Weingartner HJ, Thompson K, Vitiello B, Sunderland T. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Brain Res Rev 1992; 17: 215-26.
31. Gijsman HJ, Cohen AF, van Gerven JM. The application of the principles of clinical drug development to pharmacological challenge tests of the serotonergic system. J Psychopharmacol 2004; 18: 7-13.
32. Meibohm B, Derendorf H. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther 1997; 35: 401-13.
33. Cawello W. Connection of pharmacokinetics and pharmacodynamics - how does it work? Int J Clin Pharmacol Ther 1997; 35: 414-7.
34. Strougo A, Zuurman L, Roy C, Pinquier JL, van Gerven JM, Cohen AF, Schoemaker RC. Modelling of the concentration-effect relationship of THC on central nervous system parameters and heart rate - insight into its mechanisms of action and a tool for clinical research and development of cannabinoids. J Psychopharmacol 2008; 22: 717-26.
35. Liem-Moolenaar M, Zoethout RWM, de Boer P, Schmidt M, de Kam ML, Cohen AF, Franson KL, van Gerven JMA. The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects. J Psychopharmacol 2009; 24: 1681-7.
36. Liem-Moolenaar M, Zoethout RWM, de Boer P, Schmidt M, de Kam ML, Cohen AF, Franson KL, van Gerven JMA. The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects. J Psychopharmacol 2010; 24: 1671-9.
37. de Haas SL, de Visser SJ, van der Post JP, de Smet M, Schoemaker RC, Rijnbeek B, Cohen AF, Vega JM, Agrawal NG, Goel TV, Simpson RC, Pearson LK, Li S, Hesney M, Murphy MG, van Gerven JM. Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2, 3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers. J Psychopharmacol 2007; 21: 374-83.
38. de Haas SL, de Visser SJ, van der Post JP, Schoemaker RC, van Dyck K, Murphy MG, de Smet M, Vessey LK, Ramakrishnan R, Xue L, Cohen AF, van Gerven JM. Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2, 3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers. J Psychopharmacol 2008; 22: 24-32.
39. Zuurman L, Roy C, Schoemaker RC, Hazekamp A, Den Hartigh J, Bender JC, Verpoorte R, Pinquier JL, Cohen AF, van Gerven JM. Effect of intrapulmonary tetrahydrocannabinol administration in humans. J Psychopharmacol 2008; 22: 707-16.
40. Twa MD, Bailey MD, Hayes J, Bullimore M. Estimation of pupil size by digital photography. J Cataract Refract Surg 2004; 30: 381-9.
41. Borland RG, Nicholson AN. Visual motor co-ordination and dynamic visual acuity. Br J Clin Pharmacol 1984; 18 (Suppl. 1): 69S-72S.
42. Liem-Moolenaar M, Gray F, de Visser S, Franson K, Schoemaker R, Schmitt J, Cohen A, van Gerven J. Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol. J Psychopharmacol 2010; 24: 73-82.
43. Andrew JM. Delinquents and the tapping test. J Clin Psychol 1977; 33: 786-91.
44. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935; 18: 643-62.
45. Wellstein A, Pitschner HF. Complex dose-response curves of atropine in man explained by different functions of M1- and M2-cholinoceptors. Naunyn Schmiedebergs Arch Pharmacol 1988; 338: 19-27.
46. Duka T, Ott H, Rohloff A, Voet B. The effects of a benzodiazepine receptor antagonist beta-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills. Psychopharmacology (Berl) 1996; 123: 361-73.
47. Beal SL, Sheiner LB, Boeckmann AJ, eds. NONMEM Users Guides. Ellicott City, MD: Icon Development Solutions, 19892006.
48. Riedel W, Hogervorst E, Leboux R, Verhey F, van Praag H, Jolles J. Caffeine attenuates scopolamine-induced memory impairment in humans. Psychopharmacology (Berl) 1995; 122: 158-68.
49. Morrison JD, Reilly J. The effects of 0.025% hyoscine hydrobromide eye drops on visual function in man. Ophthalmic Physiol Opt 1989; 9: 41-5.
50. Mintzer MZ, Griffiths RR. Lorazepam and scopolamine: a single-dose comparison of effects on human memory and attentional processes. Exp Clin Psychopharmacol 2003; 11: 56-72.
51. Hutchins JB, Hollyfield JG. Acetylcholine receptors in the human retina. Invest Ophthalmol Vis Sci 1985; 26: 1550-7.
52. de Haas SL, Schoemaker RC, van Gerven JM, Hoever P, Cohen AF, Dingemanse J. Pharmacokinetics, pharmacodynamics and the pharmacokinetic/pharmacodynamic relationship of zolpidem in healthy subjects. J Psychopharmacol 2010; 24: 1619-29.
53. van Steveninck AL, Schoemaker HC, Pieters MS, Kroon R, Breimer DD, Cohen AF. A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers. Clin Pharmacol Ther 1991; 50: 172-80.
54. van Steveninck AL. Methods of assessment of central nervous system effects of drugs in man (Thesis). University of Leiden, Leiden, 1993.
55. van Steveninck AL, van Berckel BN, Schoemaker RC, Breimer DD, van Gerven JM, Cohen AF. The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation. J Psychopharmacol 1999; 13: 10-7.
56. van der Post JP, de Visser SJ, Schoemaker RC, Cohen AF, van Gerven JM. Pharmacokinetic/pharmacodynamic assessment of tolerance to central nervous system effects of a 3mg sustained release tablet of rilmenidine in hypertensive patients. J Psychopharmacol 2004; 18: 221-7.
57. Dingemanse J, van Gerven JM, Schoemaker RC, Roncari G, Oberye JJ, van Oostenbruggen MF, Massarella J, Segala P, Zell M, Cohen AF. Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Br J Clin Pharmacol 1997; 44: 477-86.
58. van Gerven JM, Roncari G, Schoemaker RC, Massarella J, Keesmaat P, Kooyman H, Heizmann P, Zell M, Cohen AF, Dingemanse J. Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Br J Clin Pharmacol 1997; 44: 487-93.
59. van Steveninck AL, Wallnofer AE, Schoemaker RC, Pieters MS, Danhof M, van Gerven JM, Cohen AF. A study of the effects of long-term use on individual sensitivity to temazepam and lorazepam in a clinical population. Br J Clin Pharmacol 1997; 44: 267-75.
60. Frey KA, Koeppe RA, Mulholland GK, Jewett D, Hichwa R, Ehrenkaufer RL, Carey JE, Wieland DM, Kuhl DE, Agranoff BW. In vivo muscarinic cholinergic receptor imaging in human brain with [11C]scopolamine and positron emission tomography. J Cereb Blood Flow Metab 1992; 12: 147-54.